Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> or = 18.~2. Has relapsed or refractory disease as defined by the following:~   * CLL - refractory to or relapsed after at least 2 prior therapies, including fludarabine, alone or in combination. Patients should not be eligible for transplantation (patients who are candidates for transplantation and have declined transplantation are eligible for this study).~  * B-cell NHL - refractory to or relapsed after at least 1 prior chemotherapy regimen and having received rituximab as a single agent or in combination with other therapies.~  * AML - refractory to or relapsed after at least 1 cycle of induction chemotherapy. Patients over the age of 70 who are not appropriate candidates for chemotherapy are eligible for this study.~  * MM - refractory to or relapsed after at least 2 prior chemotherapy regimens, including bortezomib and thalidomide or lenalidomide (except if the drug is contraindicated in a patient then this requirement is waived).~3. Disease status requirement:~   * For CLL patients, symptomatic disease that mandate treatment.~  * For B-cell NHL patients, has measurable disease by CT scan.~  * For AML patients, has \> 10% blasts in the bone marrow for refractory or relapsed disease and \> 20% blasts in the bone marrow if no prior chemotherapy.~  * For MM patients, has measurable disease defined by at least 1 of the following 3 measurements: serum M-protein \> or = to 1 g/dL, urine M-protein \> or = to 200 mg/24 h, or serum free light chain (FLC) assay with involved FLC level \> or = to 10 mg/dL provided serum FLC ratio is abnormal.~4. WHO performance status of ≤ 2.~5. For men and women of child-bearing potential, willing to use adequate contraception (i.e., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study.~6. Is able to provide written informed consent.~Exclusion Criteria:~1. Had radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment with an investigational product within 4-weeks prior to screening.~2. For CLL or NHL patients, had treatment with a short course of corticosteroids for symptom relief within 1-week prior to screening.~3. Had alemtuzumab therapy within 12-weeks prior to screening.~4. For AML patients, had treatment with hydroxyurea within 1-week prior to screening.~5. Is pregnant or nursing.~6. Has significant, ongoing co-morbid conditions which would preclude safe delivery of the study drug.~7. Has had a transplant with current active graft-versus-host-disease.~8. Has known active central nervous system involvement of the malignancy.~9. Has active, serious infection requiring systemic therapy. Patients may receive prophylactic antibiotics and antiviral therapy at the discretion of the treating physician.~10. Has significant renal or liver dysfunction.~11. Has severe thrombocytopenia requiring platelet transfusion support, unless the diagnosis is AML.~12. Has a positive test for human immunodeficiency virus (HIV) antibodies.~13. Has active hepatitis B or C. Patients with serologic evidence of prior exposure are eligible.~14. Has poorly controlled diabetes mellitus.~15. Has taken a medication that is a potent inhibitor or inducer of cytochrome P450 3A4 within 1-week prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- one arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).